<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR91">
 <label>91.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Cosimo</surname>
    <given-names>E</given-names>
   </name>
   <name>
    <surname>Tarafdar</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Moles</surname>
    <given-names>MW</given-names>
   </name>
   <name>
    <surname>Holroyd</surname>
    <given-names>AK</given-names>
   </name>
   <name>
    <surname>Malik</surname>
    <given-names>N</given-names>
   </name>
   <name>
    <surname>Catherwood</surname>
    <given-names>MA</given-names>
   </name>
   <name>
    <surname>Hay</surname>
    <given-names>J</given-names>
   </name>
   <name>
    <surname>Dunn</surname>
    <given-names>KM</given-names>
   </name>
   <name>
    <surname>Macdonald</surname>
    <given-names>AM</given-names>
   </name>
   <name>
    <surname>Guichard</surname>
    <given-names>SM</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>AKT/mTORC2 inhibition activates FOXO1 function in cll cells reducing B-Cell receptor-mediated survival</article-title>
  <source>Clin Cancer Res</source>
  <year>2019</year>
  <volume>25</volume>
  <issue>5</issue>
  <fpage>1574</fpage>
  <lpage>1587</lpage>
  <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-18-2036</pub-id>
  <?supplied-pmid 30559170?>
  <pub-id pub-id-type="pmid">30559170</pub-id>
 </element-citation>
</ref>
